Al in Omics Studies Market Report with Forecast 2026 to 2035
Share With :
Global Al in Omics Studies Market Size was valued at USD 1.21 Bn in 2025 and is predicted to reach USD 14.13 Bn by the year 2035 at a 28.0% CAGR during the forecast period for 2026 to 2035.
Al in Omics Studies Market Size, Share & Trends Analysis Report, By Offering (Software, Services), By Technology Platform (Sequencing, Epigenomics, Proteomics, Metabolomics, Others), By Application (Oncology, Infectious Diseases, Neurology, Cardiovascular Diseases, Immunology, Others), By End User (Academic and Research Institutes, Biopharmaceutical Company, Others), By Region, Forecasts, 2026 to 2035
Al in Omics Studies Market Key Takeaways:
|
The market for Al in omics investigations has grown significantly in recent years and is becoming more and more recognised globally. The omics sector is seeing a surge in AI due to the growing demand for pharmaceuticals and rising costs. The omics industry's need for AI is primarily being driven by two factors: its cost-effectiveness and the speed at which AI technology is developing.
As a result of these developments in AI technology, new software solutions with AI capabilities are being created especially for the genomics sector. We are able to examine and handle genetic data more successfully because to these more advanced and effective technologies. Numerous manual processes in omics investigations may be automated with the use of AI algorithms and software, which will save labour costs and increase the efficiency of the process.
The Al in omics studies market can be segmented based on offering, technology platform, application and end-user. By offering, the market is segmented into software and services. By technology platform, the market is segmented into sequencing, epigenomics, proteomics, metabolomics and others (transcriptomics, etc.). By application, the market is segmented into oncology, infectious diseases, neurology, cardiovascular diseases, immunology, and others (pharmacogenomics, among others). By end user, the market is segmented into academic and research institutes, biopharmaceutical company, and others (contract research organizations, among others).
The greatest percentage is expected to be accounted for by oncology over the predicted period. Research and development of medications aimed at underserved patient groups and high-value indications are funded by this sector. In addition to having a sizable market potential and providing a sizable return on investment, these objectives should make use of digital technologies like as computer learning and artificial intelligence to improve patient monitoring and selection, optimise dosage, and improve clinical trial design. Additionally, these technologies may be used to find novel indications and possible therapeutic targets.
The ability to investigate individual cells is what makes epigenomics the market leader. The resolution level it offers was previously unattainable, making it feasible to get deeper understanding of disease processes and cell behaviour. Because they make it possible to identify uncommon cell types and biomarkers that mass sequencing would miss, they have the potential to completely transform personalised medicine by enabling more accurate diagnosis and focused treatments. It has the potential to provide new therapies for a number of ailments and offer a more thorough knowledge of biological processes. Isolating and sequencing individual cells has become simpler because to developments in microfluidics, imaging, and sequencing technology.
The AI in omics studies market has expanded across North America, Latin America, Europe, the Middle East & Africa, and Asia-Pacific. In the global Al in omics studies market, artificial intelligence is most prevalent in North America. It points to a number of factors, including the prevalence of biotech and pharmaceutical businesses, supportive laws for advances in genomics and artificial intelligence, cutting-edge research facilities, and substantial financing for these fields.
In addition, other significant factors propelling the regional market include the availability of enormous data resources, the growth in partnerships between academic institutions, technology companies, and industry players, and the adoption of cutting-edge technologies like artificial intelligence and their integration into clinical applications & genomics research.
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 1.21 Bn |
| Revenue Forecast In 2035 | USD 14.13 Bn |
| Growth Rate CAGR | CAGR of 28.0% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Offering, By Technology Platform, By Application, By End-user and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
| Competitive Landscape | Thermo Fisher Scientific, Agilent Technologies, Illumina, BGI Genomics, Dassault Systemes, Qiagen, Waters Corporation, GE Healthcare, Amazon Web Services, Inc, Bruker, Danaher and Other Prominent Players. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.